Novartis, Novo Nordisk drug failures will likely ‘pop a hole in the balloon’ of the field Expert says that after resurgence in cardiovascular trials, investments will be harder to come by

https://www.statnews.com/2026/09/11/novartis-novo-nordisk-cardiovascular-drug-trials-fallout/ By Allison DeAngelis and Adam FeuersteinSept. 11, 2026 Adam Feuerstein adam.feuerstein@statnews.com Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast The Readout Loud and author of the newsletter Adam’s Biotech Scorecard. You can reach Adam on Signal at stataf.54.